Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Status:
Recruiting
Trial end date:
2025-10-14
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well lenalidomide and epcoritamab works in treating patients
with follicular lymphoma that has not been previously treated. Although follicular lymphoma
is incurable, prognosis has improved for both early and advanced stage disease, largely
attributed to therapeutic advances. Lenalidomide may stimulate or suppress the immune system
in different ways and stop cancer cells from growing and by preventing the growth of new
blood vessels that cancer cells need to grow. Epcoritamab is a bispecific monoclonal antibody
that binds to two different antigens (the part of the target that the antibody attaches to),
at the same time. This dual action allows bispecific antibodies to improve target specificity
by binding two antigens on the same cell to recruit and activate immune cells to kill cancer
cells. Lenalidomide and epcoritamab, when given together, may be more effective in treating
patients with follicular lymphoma than if they were given alone.